PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, has executed agreements with Three Rivers Provider Network (TRPN), Healthsmart Payors Organization (HPO), and Fortified Provider Network (FPN). These agreements add more than 15 million covered lives for RedPath’s patented PathFinderTG® test for pancreatic cancer.
“These contracts further validate the clinical impact PathFinderTG has in helping physicians resolve complex diagnostic dilemmas for patients at risk of pancreatic cancer,” stated Dennis M. Smith, Jr., M.D., president and chief executive officer of RedPath Integrated Pathology.
“Securing these agreements allows more patients access to PathFinderTG,” added Dr. Smith. “Published studies document the clinical value and utility of PathFinderTG and its effectiveness in decreasing the cost of managing these patients. With healthcare costs currently a major focal point for patients, clinicians and payers, this is, in fact, very exciting news.”
TRPN is one of the largest and fastest growing PPO provider network in the nation with 550,000 providers, 5,000 hospitals and 70,000 auxiliary facilities pre-approved in-network.
HPO is a national healthcare provider network consisting of directly contracted providers and affiliate networks that reduce medical expenses by contracting with hospitals, doctors and ancillary facilities across the United States. HPO consists of 277,000 secondary providers practicing in more than 476,000 locations.
FPN is a national direct-contracted preferred provider network. FPN contracts with physicians, hospitals, ancillary facilities, mid-level providers and other specialty healthcare providers who have the option of participating in a number of FNP’s product offerings.
About RedPath Integrated Pathology
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory.
The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit www.redpathip.com or contact Andrew Mignatti at 412-224-6100.